Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 1.00 |
| ▸ | CNR2 | P34972 | 2/20 | 1.00 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.63 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.63 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390949 | 1.00 | CNR1 (1.00) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3395392 | 0.87 | CNR1 (1.00) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6511967 | 0.87 | CNR1 (1.00) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3395117 | 0.86 | CNR1 (0.75) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6520141 | 0.86 | CNR1 (0.75) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10246861 | 0.83 | CNR1 (0.70) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14335869 | 0.81 | CNR1 (0.69) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14184701 | 0.80 | CNR1 (0.66) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5613910 | 0.80 | CNR1 (0.66) | CNR1CNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3588679 | 0.79 | CNR1 (0.65) | CNR1CNR2TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1370530-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002064565-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | VEGFA, EDNRA, NR1H2 | CNR1 75/4885CNR2 160/4885TAS1R3 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.